The Latest Breaking News from Pfizer

June S&P 500 E-Mini futures (ESM24) are down -0.29%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.58% this morning as the prospect of higher-for-longer U.S. interest rates continued to weigh on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

Down more than 30% in a year, pharmaceutical company Pfizer trades near its 52-week lows. Is this the right time to buy in the dip?

Initial trial results suggest that a new mRNA therapy may be able to safely and effectively treat propionic acidemia, a rare metabolic disorder.

Manipal Hospitals partners with Pfizer to enhance adult vaccination program, focusing on preventing vaccine preventable diseases efficiently.

Exclusive: Multi-dose vials could push up charge per patient, with experts warning cost could widen inequalities

Concerns that some groups who are more at risk from virus face hefty price tag, as Boots set to charge almost £100 a shot

Pharmacy to offer Pfizer/BioNTech vaccine to those not eligible for NHS booster shot from next week

The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.